Pexelizumab – a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass

Author: Fleisig Ani J   Verrier Edward D  

Publisher: Informa Healthcare

ISSN: 1471-2598

Source: Expert Opinion on Biological Therapy, Vol.5, Iss.6, 2005-06, pp. : 833-839

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content